TREATING ANKYLOSING SPONDYLITIS OF PATIENTS IN ADJARA REGION: WHY BIOLOGICAL THERAPY?
DOI:
https://doi.org/10.52340/jecm.2024.05.21Keywords:
Ankylosing Spondylitis, Biological therapy, Simponi (Golimumab), Autoimmune disease, Treatment effectivenessAbstract
BACKGROUND. Ankylosing Spondylitis is an autoimmune chronic inflammatory disease of the axial/central skeleton of human body that leads to partial or complete fusion and rigidity of spine. As Ankylosing Spondylitis have its onset typically in late adolescents or middle age group, it is quite necessary to have a hold on it. Ankylosing Spondylitis was thought of having a bad prognosis earlier but in recent few years, with help of research advancement techniques a totally new and highly effective treatment known as biological therapy is used.
OBJECTIVE. Our aim was to identify the outcome with biological treatment of 29 patients which got biological medication TNF (tumor necrosis factor) inhibitor Simponi (Golimumab). We evaluated the effectiveness of managing Ankylosing Spondylitis with biological therapy in Adjara region. As this is an autoimmunity disorder and it may affect any person especially the young and middle age people, everyone must be educated about getting biologic treatment as soon as possible so that they immediately get control over the disease progression.
MATERIALS AND METHODS. We investigated 29 patients of Ankylosing Spondylitis (22 males and 7 females) from 24 yrs. old to 65 yrs. old age-group. We used the biological therapy with TNF-α inhibitor named Simponi (Golimumab). 50 mg of Golimumab was injected once a month subcutaneously in the beginning of therapy. We identified pain intensity, levels of CRP and ESR in all recruited patients since the first day over a period of 3 months, 6 months, and 12 months. Accordingly, doses were decreased from once a month to once in three months. The study was conducted at the clinic “Solo-med” during the period of 2022 October to 2023 December.
RESULTS. The effectiveness of biological treatment with Simponi (Golimumab) is appreciated as it has shown a significant reduction in symptoms of Ankylosing Spondylitis such as the pain intensity, levels of CRP and ESR. About Pain intensity – After 3 months, light pain intensity was in about 18% of males with 14% of females and moderate pain intensity was in about 64% of males with 71% of females. It decreased and after 12 months, now moderate pain intensity was in about 22% of males and severe pain intensity was in none of the males. But in contrast, the female patients had neither severe nor moderate pain intensity rather they all had light pain intensity. About CRP – In the beginning all patients including both males and females had an increased level of CRP. It decreased and after 12 months only 9% of males and 8% of females had an increased CRP. About ESR – In the beginning 95% of males and 85% of females had an increased ESR. It decreased quickly with biological therapy and consequently after 12 months of treatment only 1 patient had increased ESR. After receiving Golimumab, 3 patients had episodes of acute rhinitis within 2 months, 2 patients had minor sneezing for 3 months as side effects, 5 patients had general weakness just after getting injection. 3 patients had urinary tract infection for 1 month as complication. And, no one had any serious complications.
CONCLUSION. According to these studies, it can be said that biologics have improved the quality of life of these patients by improving body mobility, flexibility and preventing complications from internal organs. To take care of the youth, use of biological therapy is advised so that the disease do not progress any further. Biological therapy is a present-day superlative method to manage Ankylosing Spondylitis as it reaches a stable remission period and alleviates the symptoms of Ankylosing Spondylitis.
Downloads
References
C. Wen et al., “Quantitative metagenomics reveals unique gut microbiome biomarkers in ankylosing spondylitis,” Genome Biol, vol. 18, no. 1, 2017, doi: 10.1186/s13059-017-1271-6.
W. Zhu et al., “Ankylosing spondylitis: etiology, pathogenesis, and treatments,” Bone Research, vol. 7, no. 1. 2019. doi: 10.1038/s41413-019-0057-8.
Y. Xiong et al., “Joint together: The etiology and pathogenesis of ankylosing spondylitis,” Frontiers in Immunology, vol. 13. 2022. doi: 10.3389/fimmu.2022.996103.
H. T. Liao et al., “The Potential Role of Genetics, Environmental Factors, and Gut Dysbiosis in the Aberrant Non-Coding RNA Expression to Mediate Inflammation and Osteoclastogenic/Osteogenic Differentiation in Ankylosing Spondylitis,” Frontiers in Cell and Developmental Biology, vol. 9. 2022. doi: 10.3389/fcell.2021.748063.
E. N. Kubiak, R. Moskovich, T. J. Errico, and P. E. Di Cesare, “Orthopaedic management of ankylosing spondylitis.,” J Am Acad Orthop Surg, vol. 13, no. 4, 2005, doi: 10.5435/00124635-200507000-00006.
N. Sharma et al., “Usage of conventional PCR technology for the detection of HLA-B27 allele: A significant molecular marker of ankylosing spondylitis,” Indian Journal of Clinical Biochemistry, vol. 28, no. 2, 2013, doi: 10.1007/s12291-012-0261-4.
L.-S. Tam, J. Gu, and D. Yu, “Pathogenesis of ankylosing spondylitis,” Nat Rev Rheumatol, vol. 6, no. 7, pp. 399–405, Jul. 2010, doi: 10.1038/nrrheum.2010.79.
S. Byravan, A. Moorthy, “P269 Is there a correlation between ethnicity and severity of axial spondyloarthropathy?,” Rheumatology, 2022: 61(1). doi: 10.1093/rheumatology/keac133.268.
N. Tsintsadze, N. Tsivadze, I. Kakhidze, et al. “Frequent Cases of Spondylarthritis and Hereditary Propensity (HLA-B27) in the Same Family Name Relatives from the Keda Region of Ajara, Georgia,” GEORGIAN BIOMEDICAL NEWS, 2023, doi: 10.52340/gbmn.2023.01.01.18.
L. E. Dean, G. T. Jones, A. G. Macdonald, et al. “Global prevalence of ankylosing spondylitis,” Rheumatology (United Kingdom), vol. 53, no. 4, 2014, doi: 10.1093/rheumatology/ket387.
S. Almousa, N. Alshamaa, H. Wannous, K. Khder, and H. Qasem, “Gender-related differences in axial spondyloarthritis (axSpA) patients,” Egyptian Rheumatologist, vol. 45, no. 1, 2023, doi: 10.1016/j.ejr.2022.08.003.
H. S. Goei The, M. M. Steven, S. M. Van Der Linden, and A. Cats, “Evaluation of diagnostic criteria for ankylosing spondylitis: A comparison of the Rome, New York and modified New York criteria in patients with a positive clinical history screening test for ankylosing spondylitis,” Rheumatology, vol. 24, no. 3, 1985, doi: 10.1093/rheumatology/24.3.242.
M. C. Hwang, L. Ridley, and J. D. Reveille, “Ankylosing spondylitis risk factors: a systematic literature review,” Clinical Rheumatology, vol. 40, no. 8. 2021. doi: 10.1007/s10067-021-05679-7.
P. J. Mease, “Suspecting and Diagnosing the Patient with Spondyloarthritis and What to Expect from Therapy,” Medical Clinics of North America, vol. 105, no. 2. 2021. doi: 10.1016/j.mcna.2020.10.001.
R. Hintenberger, B. Affenzeller, et al. “Cardiovascular risk in axial spondyloarthritis-a systematic review,” Clinical Rheumatology, vol. 42, no. 10. 2023. doi: 10.1007/s10067-023-06655-z.
J. Sieper, “Management of ankylosing spondylitis/axial spondyloarthritis,” Rheumatology: Sixth Edition, vol. 2–2, pp. 970–985, Jan. 2015, doi: 10.1016/B978-0-323-09138-1.00118-2.
S. Ramiro et al., “ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update,” Ann Rheum Dis, vol. 82, no. 1, 2022, doi: 10.1136/ard-2022-223296.
S. Kiwalkar, A. Deodhar, and J. Sieper, “Treatment Guidelines for Axial Spondyloarthritis,” Axial Spondyloarthritis, pp. 243–258, Jan. 2019, doi: 10.1016/B978-0-323-56800-5.00016-3.
D. E. Furst and J. S. Louie, “Targeting inflammatory pathways in axial spondyloarthritis,” Arthritis Research and Therapy, vol. 21, no. 1. 2019. doi: 10.1186/s13075-019-1885-z.
M. M. Ward et al., “American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network 2015 Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis,” Arthritis and Rheumatology, vol. 68, no. 2, 2016, doi: 10.1002/art.39298.
M. M. Ward et al., “2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis,” Arthritis and Rheumatology, vol. 71, no. 10, 2019, doi: 10.1002/art.41042.
S. D’Angelo et al., “Effectiveness of Golimumab as Second Anti-TNFα Drug in Patients with Rheumatoid Arthritis, Psoriatic Arthritis and Axial Spondyloarthritis in Italy: GO-BEYOND, a Prospective Real-World Observational Study,” J Clin Med, vol. 11, no. 14, 2022, doi: 10.3390/jcm11144178.
Downloads
Published
How to Cite
Issue
Section
